FOXO Acquires Vector BioSource, Projecting $1 Million Revenue for 2025
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 15 2025
0mins
Source: Globenewswire
- Business Expansion: FOXO's acquisition of Vector BioSource enhances its footprint in the pharmaceutical services sector, projecting approximately $1 million in net revenue for 2025, thereby strengthening its market position in biotechnology and pharmaceutical research.
- Healthcare Service Growth: Since opening in August 2023, Myrtle Recovery Centers has served patients from 63 counties in Tennessee, with projected admissions of 550 in 2025, a significant increase from 195 in 2024, indicating strong demand in the addiction treatment sector.
- Financial Improvement: FOXO reported net revenues of approximately $12 million for the nine months ended September 30, 2025, expecting to exceed $15 million for the full year, while equity increased from $5.3 million at the end of 2024 to $20.2 million by September 2025, reflecting substantial financial health improvements.
- Strategic Investment: FOXO established a wholly-owned subsidiary, FOXO Acquisition Corporation, to facilitate growth through acquisitions and introduced Series E Preferred Stock to fund future acquisitions, further solidifying its market position.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
